Top of this page
Skip navigation, go straight to the content

Our Science Pipeline



Our pipeline builds the basis of UCB’s future, so our focus is on breakthrough innovative approaches with the goal of developing new highly differentiated solutions that will significantly impact the lives of patients. We have developed unique partnerships with patients at every step of the clinical development process to identify needs and inform study design and operations.

  Indications Phase 1 Phase 2 Phase 3 Filing
bimekizumab (IL17AF)psoriasisphase 3
 psoriatic arthritisphase 3 half
 axial spondyloarthritisphase 3 half
 hidradenitis suppurativa
phase 3 half
zilucoplan (C5)myasthenia gravisphase 3 half
rozanolixizumab (FcRn)myasthenia gravisphase 3 half
 immune thrombocytopeniaphase 3 half
 MOG-antibody diseasephase 2
 autoimmune encephalitisphase 1
dapirolizumab pegol (CD40L)systemic lupus erythematosus1phase 3 half
Staccato® alprazolamactive epileptic seizurephase 2
bepranemab (anti-tau antibody)
Alzheimer's disease2phase 2 half
UCB0599 (α-syn-misfolding inhibitor)Parkinson's diseasephase 2 half
5 Projects phase 1 half

1 In partnership with Biogen

2 In partnership with Roche/Genentech


Zilucoplan in amyotrophic lateral sclerosis (ALS) by HEALEY ALS Platform Trial

MOG: myelin oligodendrocyte glycoprotein-antibody disease